Astellas Institute for Regenerative Medicine
Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas Pharma Inc., is a pioneering entity in the field of regenerative medicine, headquartered in the United States. Established in 2007, AIRM focuses on developing innovative cell therapies aimed at addressing unmet medical needs, particularly in the areas of oncology and rare diseases.
With a commitment to advancing scientific research, AIRM has achieved significant milestones, including the development of unique cell-based therapies that leverage cutting-edge technology. The institute's core offerings include advanced cell therapy products that stand out for their potential to transform patient outcomes.
Recognised for its contributions to the regenerative medicine landscape, AIRM continues to solidify its market position through strategic partnerships and a robust pipeline of therapeutic candidates, driving forward the future of healthcare.
+16 vs industry average
Astellas Institute for Regenerative Medicine’s score of 54 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Astellas Institute for Regenerative Medicine?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Astellas Institute for Regenerative Medicine yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Astellas Institute for Regenerative Medicine’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Astellas Institute for Regenerative Medicine yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Astellas Pharma Inc.
Carbon Disclosure Project
Inherited from Astellas Pharma Inc.The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project